Following publication of ‘The United Kingdom’s Exit from, and New Partnership with, the European Union’ White Paper, the Association of the British Pharmaceutical Industry (ABPI) has issued the following statement.
Mike Thompson, ABPI, Chief Executive said:
"Today’s White Paper sets out the right ambitions for negotiating a smooth and orderly exit from the European Union, providing a welcome opportunity for proper parliamentary and public scrutiny.
For Britain to be one of the best places in the world for science and innovation, seeking to negotiate barrier-free collaboration is a welcome approach. Major medical, research and public health initiatives are predicated on this.
In important areas such as medicines regulation, we believe negotiating cooperation and alignment with the European Medicines Agency is a win-win for the UK and EU, and is the best way of ensuring patients continue to benefit from the very latest clinical developments and innovative treatments.”
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.